Business
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
CNBC·October 29, 2026
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Read the full story at CNBC →